Cabaletta Bio (CABA) Liabilities and Shareholders Equity (2018 - 2025)

Cabaletta Bio has reported Liabilities and Shareholders Equity for 8 years, with the latest figure at $165.1 million in Q4 2025.

• For the quarter ending Q4 2025, Liabilities and Shareholders Equity fell 10.79% year-over-year to $165.1 million; the trailing twelve-month figure through Dec 2025 stood at $744.5 million (down 12.14% YoY), and the FY2025 full-year result was $165.1 million, down 10.79% from the prior year.
• Liabilities and Shareholders Equity for Q4 2025 stood at $165.1 million, down from $189.8 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $253.6 million in Q4 2023, with the low at $91.7 million in Q3 2022.
• Average Liabilities and Shareholders Equity over 5 years is $159.7 million, with a median of $165.1 million recorded in 2025.
• Year-over-year, Liabilities and Shareholders Equity jumped 132.44% in 2024 and plunged 31.32% in 2025.
• Tracing CABA's Liabilities and Shareholders Equity over 5 years: stood at $126.3 million in 2021, then fell by 7.42% to $117.0 million in 2022, then surged by 116.85% to $253.6 million in 2023, then fell by 27.05% to $185.0 million in 2024, then dropped by 10.79% to $165.1 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $165.1 million (Q4 2025), $189.8 million (Q3 2025), and $224.5 million (Q2 2025), per Business Quant data.

Peer Comparison